

Amendments To The Claims

Claims 1-6 (Canceled)

Claim 7 (Currently Amended) An antibody or fragment thereof ~~A binding compound~~ which specifically binds to an isolated polypeptide consisting of the amino acid sequence of SEQ ID NO: 6 ~~the polypeptide of claim 4.~~

Claim 8 (Canceled)

Claim 9 (Currently Amended) The antibody of claim 8, ~~binding compound of claim 8~~ wherein said ~~the~~ antibody is a monoclonal antibody.

Claims 10-16 (Canceled)

Claim 17 (New) A hybridoma that produces the antibody of claim 7.

Claim 18 (New) The fragment of claim 7, wherein said fragment is a Fab, Fv or antibody half molecule.

Claim 19 (New) The antibody or fragment thereof of claim 7, wherein said antibody or fragment thereof is bound to a solid support.

Claim 20 (New) A pharmaceutical formulation comprising the antibody or fragment thereof of claim 7 and one or more pharmaceutically acceptable carriers.

Claim 21 (New) The pharmaceutical formulation of claim 20, wherein said formulation is suitable for parenteral administration.

Claim 22 (New) The pharmaceutical formulation of claim 21, wherein said parenteral administration is subcutaneous administration.

Claim 23 (New) The pharmaceutical formulation of claim 21, wherein said parenteral administration is intravenous administration.

Claim 24 (New) A unit dose comprising the pharmaceutical formulation of claim 20.

Claim 25 (New) The antibody or fragment thereof of claim 7, wherein said antibody or fragment thereof is a recombinant therapeutic antibody or fragment.

Claim 26 (New) A pharmaceutical formulation comprising the antibody or fragment thereof of claim 25 and one or more pharmaceutically acceptable carriers.

Claim 27 (New) The pharmaceutical formulation of claim 26, wherein said formulation is suitable for parenteral administration.

Claim 28 (New) The pharmaceutical formulation of claim 27, wherein said parenteral administration is subcutaneous administration.

Claim 29 (New) The pharmaceutical formulation of claim 27, wherein said parenteral administration is intravenous administration.

Claim 30 (New) A unit dose comprising the pharmaceutical formulation of claim 26.